TICKERNERD
Menu
NMTCNMTCHealthcare · Medical Devices

NMTC Stock Forecast: NeuroOne Medical Technologies Corp. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.93
−4.41% on the day

The 3 Wall Street analysts covering NeuroOne Medical Technologies Corp. hold a median 12-month price target of $8 — +762.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.4M
Ticker Nerd rank
38/ 100
Median analyst target
$8.00
Analysts covering
3
Revenue$2.0M+16.3% y/y
Operating income−$2.4M
Net income−$2.0M
Free cash flow−$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.9%
1M
−10.0%
YTD
−79.6%
1Y
−80.5%
From 52W high
−84.2%
From 52W low
+15.3%
$0.80
$5.89
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NMTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NeuroOne Medical Technologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
38/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Quality
60
Issuance
58
Revisions
56
Accruals
50
Volatility
39
Value
31
Growth
25
Momentum
3

Size (92): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NMTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NMTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26NMTCHigh $8.80Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.00Median $8.00High $8.80

The green dot is the last close — the median target sits +762.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Maxim GroupMaintainsBuy$13 → $5.00
13 May 2026Ladenburg ThalmannMaintainsBuy$1.60 → $8.00
13 May 2026Ladenburg ThalmannMaintainsBuy—
2 Mar 2026Jones TradingInitiatesBuy—
9 Sept 2025Maxim GroupInitiatesBuy—
5 May 2025Ladenburg ThalmannInitiatesBuy—
15 Aug 2023Alliance Global PartnersMaintainsBuy—
28 Mar 2022Craig-HallumDowngradeHold—
3 Dec 2021Alliance Global PartnersInitiatesBuy—
15 Nov 2021Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NMTC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NMTC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, NeuroOne Medical Technologies Corp. returned −80.5% against +12.4% for the S&P 500, dividends included.

NMTC vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26NMTCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NMTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

NeuroOne Medical Technologies Corp. (NMTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 86% of US stocks

Price / sales
0.7×

Cheaper than 75% of US stocks

Price / book
2.1×

Cheaper than 38% of US stocks

EV / EBITDA
−0.9×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
16.3%

Higher than 64% of US stocks

Earnings growth (YoY)
16.3%

Higher than 55% of US stocks

Gross margin
59.9%

Higher than 73% of US stocks

Operating margin
−122.9%

Higher than 13% of US stocks

Net margin
−59.7%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−124.7%

Higher than 11% of US stocks

Return on assets
−58.1%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NeuroOne Medical Technologies Corp. (NMTC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NeuroOne Medical Technologies Corp. has a market value of $8.4M and an enterprise value of $6.6M.

  • Revenue in the twelve months to 30 June 2026: $9.5M. The latest quarter grew 16.3% year on year.

  • Net income over the same four quarters: −$7.4M, a −78.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$7.2M.

  • NeuroOne Medical Technologies Corp. spent $70K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 8.7M.

  • Trailing P/E: −1.7×; forward P/E: −3.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • NeuroOne Medical Technologies Corp. employs 18 people — $526K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

NMTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NMTCNeuroOne Medical Technologies Corp.$8.4M38
AEMDAethlon Medical, Inc.$8.7M29
BMRABiomerica, Inc.$7.9M14
INBSIntelligent Bio Solutions, Inc.$5.8M16
IRIXIRIDEX Corp.$12.2M77
PLSMPulsenmore Ltd.$12.8M—
SINTSINTX Technologies, Inc.$12.8M28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NeuroOne Medical Technologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NMTC news & analysis

NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System

GlobeNewsWire · 29 Oct 2026positive

NeuroOne announced that initial clinical results for its OneRF Trigeminal Nerve Ablation System were published in the peer-reviewed journal Pain Management. The reported study found immediate pain freedom in 14 of 15 patients, with all patients achieving favorable pain outcomes at a mean six-month follow-up.

Why it matters — The publication provides clinical findings on the OneRF system, including outcomes and use of its multi-contact probe for mapping and treatment without repeated repositioning.

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

GlobeNewsWire · 22 Oct 2026positive

NeuroOne announced its first pharmaceutical industry purchase order for its StereoCED™ drug delivery platform, supporting a research program at a Tier 1 global pharmaceutical company.

Why it matters — The purchase order marks the platform’s first reported pharmaceutical industry order and relates to a global company’s research program.

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

GlobeNewsWire · 5 Oct 2026positive

NeuroOne Medical Technologies reported preliminary, unaudited fourth fiscal quarter product revenue of $3.8 million, reflecting 38.4% growth, and preliminary full-year product revenue up 15.6% to $10.5 million, at the top of its guidance range. The company also announced it secured a record $4.5 million purchase order.

Why it matters — This update signals accelerating quarterly revenue growth, annual revenue at the top of guidance, and a record purchase order, all of which are relevant indicators for NMTC watchers tracking the company's commercial momentum.

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

GlobeNewsWire · 17 Sept 2026positive

NeuroOne Medical Technologies announced a new Southern California distribution agreement for its FDA-cleared OneRF Trigeminal Nerve Ablation System, expanding U.S. commercialization of the product. The agreement was announced on September 17, 2026.

Why it matters — A NMTC watcher would care because this distribution agreement broadens the commercial reach of the company's FDA-cleared product in a key U.S. market.

FAQ

Frequently asked questions about NMTC stock

What is the NMTC stock price forecast for 2026-2027?

The 3 Wall Street analysts covering NeuroOne Medical Technologies Corp. have a median 12-month price target of $8, with estimates ranging from $5 to $8.8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NMTC stock a buy right now?

Of the 3 analysts covering NeuroOne Medical Technologies Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeuroOne Medical Technologies Corp. 38 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NMTC?

As at 31 Oct 2026, NeuroOne Medical Technologies Corp. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will NMTC stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +762.8% from the last close, and Ticker Nerd's factor model ranks NeuroOne Medical Technologies Corp. 38 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NMTC stock forecast for 2030?

No analyst covering NeuroOne Medical Technologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NMTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8.8 over the next 12 months.

How has NMTC stock performed over the past year?

NeuroOne Medical Technologies Corp. returned -80.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeuroOne Medical Technologies Corp. do?

NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery.

What is the latest news on NMTC?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System". NeuroOne announced that initial clinical results for its OneRF Trigeminal Nerve Ablation System were published in the peer-reviewed journal Pain Management. The reported study found immediate pain freedom in 14 of 15 patients, with all patients achieving favorable pain outcomes at a mean six-month follow-up.

Company

About NeuroOne Medical Technologies Corp.

NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery. Its product portfolio includes Evo cortical electrodes, Evo sEEG electrodes, and OneRF ablation systems designed for neurosurgery, neurology, and pain management applications. NeuroOne Medical Technologies Corporation serves clinical settings that treat conditions such as epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremor, and chronic pain. Based in Eden Prairie, Minnesota, the company plays a specialized role in the neurotechnology market by supporting more precise monitoring and treatment options for patients with complex brain and nerve-related disorders.

CEO Mr. David A. Rosa M.D. · 18 employees · United States · https://nmtc1.com